Detail akcie Senseonic Hldgs Rg online

Business Summary: Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems Eversense 365 and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. Its CGM systems are indicated for continually measuring glucose levels for up to 365 days for Eversense 365 and 180 days for Eversense E3 in persons with diabetes age 18 and older. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Senseonics Holdings Inc revenues increased 48% to $21M. Net loss decreased 24% to $48.3M. Revenues reflect United States segment increase of 26% to $6.4M. Lower net loss reflects Glucose monitoring Products segment loss decrease of 68% to $19.6M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.04 to -$1.19.